Periodic Reporting for period 1 - BEAMER (BEhavioral and Adherence Model for improving quality, health outcomes and cost-Effectiveness of healthcaRe)
Período documentado: 2021-09-01 hasta 2022-08-31
Adherence is important to maximize patients' benefit of treatment and therapy, a key factor for a variety of subsequent health outcomes.
On average 25%, of patients are non-adherent to prevention activities and disease management activities including medication intake, appointment scheduling, screening, exercise, and dietary changes. Some estimates show that nearly 50% of patients fail to adhere to treatment recommendations. When preventive or treatment regimens are complex and/or require lifestyle changes and modification of existing habits, non-adherence can be as high as 70%.
Medication non-adherence has been identified as a major barrier to effectively manage chronic conditions, leading to poorer health outcomes among patients, higher rates of hospitalization, and increased mortality. In fact, each year, as many as 125.000 premature deaths in the US and 200.000 in the EU are related to non-adherence, which causes personal suffering and significant cost burden on healthcare systems.
As a consequence, this eventually causes additional financial burden on healthcare systems and overall societal cost.
The EU-funded BEAMER project aims to collate the factors affecting non-adherence, including behavioural factors, into a computational model which can provide a solid foundation for understanding the problem and, hence, improve the effectiveness of future solutions. The aim of the model is to identify the actionable factors driving adherence and the enable the segmentation of the population based on specific needs for better targeting of support to the individual patient.
On average 25%, of patients are non-adherent to prevention activities and disease management activities including medication intake, appointment scheduling, screening, exercise, and dietary changes. Some estimates show that nearly 50% of patients fail to adhere to treatment recommendations. When preventive or treatment regimens are complex and/or require lifestyle changes and modification of existing habits, non-adherence can be as high as 70%.
Medication non-adherence has been identified as a major barrier to effectively manage chronic conditions, leading to poorer health outcomes among patients, higher rates of hospitalization, and increased mortality. In fact, each year, as many as 125.000 premature deaths in the US and 200.000 in the EU are related to non-adherence, which causes personal suffering and significant cost burden on healthcare systems.
As a consequence, this eventually causes additional financial burden on healthcare systems and overall societal cost.
The EU-funded BEAMER project aims to collate the factors affecting non-adherence, including behavioural factors, into a computational model which can provide a solid foundation for understanding the problem and, hence, improve the effectiveness of future solutions. The aim of the model is to identify the actionable factors driving adherence and the enable the segmentation of the population based on specific needs for better targeting of support to the individual patient.
The main objective of BEAMER for Year 1 (September 2021 to August 2022) was to collect the state of the art on adherence to treatment from field experts, citizens and the scientific literature. The implemented tasks resulted in the establishment of a common ground for the project, with the creation of definitions for some major concepts that will define the scope of the upcoming project developments (such as “adherence to treatment”, “actionability” and “patient journey”, for example). These findings were reported in the deliverable entitled “Comprehensive overview of the findings of state-of-the-art concerning definition of adherence and methodologies planned for assessing the data”. We have also carried out a literature review to identify frameworks and theoretical models on behavioural models and adherence, as well as the most relevant factors and dimensions influencing patient’s adherence to treatment.
Furthermore, we have mapped out the existing data sources on these factors, and where we found gaps that needed to be surpassed, we designed data collection methodologies.
Finally, by knowing where our focus lied, based upon the prioritisation done at the first stages of the project as a result of the literature review and the Delphi consensus, we have been able to lay out the main conceptual framework of the model.
Furthermore, we have mapped out the existing data sources on these factors, and where we found gaps that needed to be surpassed, we designed data collection methodologies.
Finally, by knowing where our focus lied, based upon the prioritisation done at the first stages of the project as a result of the literature review and the Delphi consensus, we have been able to lay out the main conceptual framework of the model.
The main output of this project will be a disease-agnostic behavioral and adherence model for improving quality, health outcomes and cost-effectiveness of healthcare, through the improvement of the quality of life of individuals, enhancement of healthcare accessibility and sustainability. The model will allow for tailoring to individual's needs, using Real World Data captured from patients' behaviors and health system information, transforming the way healthcare stakeholders engage with patients to optimize understanding of their condition and adherence levels throughout their patient journey.
BEAMER will optimize the disease-agnostic adherence model by real-life testing proof-of-concept in 18 different pilots in Norway, Spain, the Netherlands, Germany, Portugal, and Italy, including over 18,000 patients (3000 patients in each thematic area). BEAMER will be embodied in an open source European searchable database, continuously updated, validated and optimized by empirical evidence and new insights, available to all stakeholders and adaptable for future developments in healthcare. Finally, extensive efforts will be directed to develop and implement dissemination and communication activities that increase exploitation and sustainability of BEAMER.
The impact of the model implementation is hopefully the reform of the way healthcare is provided. By putting the patient at the core of its system, we aim to deliver high-value personalised care, increase the adherence of patients to therapy, and lead to a significant decrease in healthcare costs across Europe.
BEAMER will optimize the disease-agnostic adherence model by real-life testing proof-of-concept in 18 different pilots in Norway, Spain, the Netherlands, Germany, Portugal, and Italy, including over 18,000 patients (3000 patients in each thematic area). BEAMER will be embodied in an open source European searchable database, continuously updated, validated and optimized by empirical evidence and new insights, available to all stakeholders and adaptable for future developments in healthcare. Finally, extensive efforts will be directed to develop and implement dissemination and communication activities that increase exploitation and sustainability of BEAMER.
The impact of the model implementation is hopefully the reform of the way healthcare is provided. By putting the patient at the core of its system, we aim to deliver high-value personalised care, increase the adherence of patients to therapy, and lead to a significant decrease in healthcare costs across Europe.